Celldex Therapeutics Inc. (CLDX)

2.37
NASDAQ : Health Technology
Prev Close 2.36
Day Low/High 2.33 / 2.38
52 Wk Low/High 2.20 / 3.94
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 135.99M
Market Cap 329.08M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting CLDX Call Options For December 15th

Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the December 15th expiration.

Short Interest Declines 42.3% For CLDX

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 5,261,068 share decrease in total short interest for Celldex Therapeutics, Inc. , to 7,177,400, a decrease of 42.30% since 09/15/2017.

Interesting CLDX Put And Call Options For May 2018

Interesting CLDX Put And Call Options For May 2018

Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the May 2018 expiration.

Interesting CLDX Call Options For October 20th

Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the October 20th expiration.

Celldex Reports Second Quarter 2017 Results

Celldex Reports Second Quarter 2017 Results

Conference Call Scheduled for Tuesday, August 8 at 4:30 p.m. Eastern Time

Celldex To Report Second Quarter 2017 Financial Results And Host Corporate Update Call

Celldex To Report Second Quarter 2017 Financial Results And Host Corporate Update Call

Conference Call Scheduled for Tuesday, August 8 at 4:30 p.m. Eastern Time

September 15th Options Now Available For Celldex Therapeutics (CLDX)

September 15th Options Now Available For Celldex Therapeutics (CLDX)

Investors in Celldex Therapeutics, Inc. saw new options become available today, for the September 15th expiration.

Celldex Therapeutics Presents Phase 1 Study Of Varlilumab And Opdivo® At 2017 ASCO Annual Meeting

Early signs of clinical activity without increased toxicity observed

Celldex Presents Promising Overall Survival Data From Phase 2 Study Of Single-agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma

Combination study with checkpoint inhibitor currently enrolling; data from combination arm with varlilumab anticipated in fall of 2017

First Week Of November 17th Options Trading For Celldex Therapeutics (CLDX)

Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.

Celldex Provides Corporate Update And Reports Full Year 2016 Results

Conference Call Scheduled for 4:30 p.m. ET Today

First Week of CLDX March 17th Options Trading

Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the March 17th expiration.

Are People Finally Noticing?

Recognition of the market's inertia seems to be growing.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

TheStreet Quant Rating: D (Sell)